BofA raises Ardent Health stock price target on acquisition upside
BofA Securities raised its price target on Ardent Health Partners (ARDT) to $14 from $12, citing the company's acquisition of Boone Health. The stock trades at $17.68, near its 52-week high. BofA expects the deal to add $5M-$10M in EBITDA in the first year, growing to $30M-$40M by the third year. Ardent reported Q3 2026 earnings of $0.31 per share, beating estimates. Mizuho also raised its target to $21, maintaining an Outperform rating.
How this was made
The 30-second read
Why it matters
The analyst's target reduction and sustained Underperform rating suggest a near‑term bearish bias for ARDT.
Market read
The price‑target change directly affects ARDT investors and may influence sentiment in the health‑services sector.
What to watch
Potential synergies and cash‑flow benefits from Boone Health may be undervalued by the analyst.
Background
BofA Securities updated its valuation model for ARDT after the company announced a $47 million cash acquisition of Boone Health, projecting incremental EBITDA over the next three years.
Ticker impact
BofA raised its price target on Ardent Health Partners to $14, citing the Boone Health acquisition and added EBITDA potential.
likely downward pressure as the market prices in the lower target and rating.
The new target is $14 versus the $17.68 market price, and the rating remains Underperform, indicating limited upside.
Market effects
May weigh on the broader health‑services sector as analysts reassess acquisition premiums.
Limited to U.S. healthcare stocks; no broader regional effect.
Minimal global impact beyond U.S. small‑cap healthcare investors.
Counterpoint
The acquisition could unlock longer‑term earnings growth, making the current target overly conservative.
Key entities
- companyArdent Health Partners Inc
U.S. health‑services operator (NYSE: ARDT) acquiring Boone Health.
- analystBofA Securities
Investment bank raising ARDT price target to $14.
